Neurofeedback to Treat Depression

Description

This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD (60 in R61 phase and 80 in R33 Phase). This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamically modulate task stimuli (in a closed loop) based on this state.

Conditions

MDD

Talk to us

Study Overview

On this page

Study Details

Study overview

This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD (60 in R61 phase and 80 in R33 Phase). This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamically modulate task stimuli (in a closed loop) based on this state.

Reducing Neural Perseveration Through Closed Loop Real Time fMRI Neurofeedback to Alleviate Depressive Symptoms

Neurofeedback to Treat Depression

Condition
MDD
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Center for Neuromodulation in Depression and Stress, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * gender, inclusive
  • * adult aged 18 - 65 meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for MDD according to the Clinician-Administered MDD Scale for DSM-5 (unipolar depression or bipolar II depressed)
  • * scores at least a minimum score of 16 on Montgomery Asberg Depression Rating Scale (MADRS)
  • * normal cognition
  • * participants must be able to read and understand English
  • * participants must be able to provide consent
  • * pregnancy (female participants)
  • * outside age range
  • * MRI contraindications (medical implant, claustrophobia, etc.)
  • * use of psychoactive medication (including antidepressants) or currently in therapy
  • * neurological disorder or any condition that in the view of the PI could impact brain data, cause depression, require medication that could cause depressive symptoms, or otherwise result in participant being unfit for study (for example, co-morbid psychotic, neurological disorders, developmentally or cognitively disabled/impaired, active alcohol or drug abuse/dependence within the past 6 months).
  • * non-English speaking
  • * non-correctable vision loss
  • * refusal to provide informed consent
  • * representing an active suicide risk

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Pennsylvania,

Yvette I Sheline, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

2024-12-31